These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 619956)

  • 1. Immunoadherence and complement in cancer-bearing mice.
    Porta C; Villa ML; Clerici E
    Br J Cancer; 1978 Jan; 37(1):23-7. PubMed ID: 619956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement receptor binding of C3b-coated cells treated with C3b inactivator, beta 1H globulin and trypsin.
    Carlo JR; Ruddy S; Studer EJ; Conrad DH
    J Immunol; 1979 Aug; 123(2):523-8. PubMed ID: 88474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enhancement of the therapeutic effect and red cell immune function by radix Trichosanthis in mice bearing Ehrlich ascites carcinoma].
    Guo F
    Zhong Xi Yi Jie He Za Zhi; 1989 Jul; 9(7):418-20, 390. PubMed ID: 2791164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.
    Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Jun; 153(6):1592-603. PubMed ID: 7252421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.
    Whaley K; Thompson RA
    Immunology; 1978 Dec; 35(6):1045-9. PubMed ID: 83964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.
    Ross GD; Lambris JD; Cain JA; Newman SL
    J Immunol; 1982 Nov; 129(5):2051-60. PubMed ID: 6214588
    [No Abstract]   [Full Text] [Related]  

  • 8. Complement receptors (C3b, C4b/C3d) unbalance on CLL lymphocytes.
    Perussia B; Casali P; Joppolo G; Borzini P
    Boll Ist Sieroter Milan; 1976 Jul; 55(3):235-40. PubMed ID: 1087884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ehrlich ascites cells activate the alternative pathway of the human complement system.
    Betz M; Hänsch GM; Shin ML
    Immunobiology; 1984 May; 166(4-5):397-402. PubMed ID: 6237046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of the C3b-inactivator on the cell-bound C3b.
    Law SK; Fearon DT; Levine RP
    J Immunol; 1979 Mar; 122(3):759-65. PubMed ID: 448074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assay for the two different types of lymphocyte complement receptors.
    Ross GD; Polley MJ
    Scand J Immunol; 1976 Jun; Suppl 5():99-111. PubMed ID: 1053233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of soluble C3 fragments with guinea pig lymphocytes. Comparison of effects of C3a, C3b, C3c, and C3d on lymphokine production and lymphocyte proliferation.
    Koopman WJ; Sandberg AL; Wahl SM; Mergenhagen SE
    J Immunol; 1976 Jul; 117(1):331-6. PubMed ID: 932430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres.
    Lambris JD; Ross GD
    J Immunol; 1982 Jan; 128(1):186-9. PubMed ID: 7033372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-binding sites on C3 and C3b.
    Dierich MP; Bokisch VA
    J Immunol; 1977 Jun; 118(6):2145-50. PubMed ID: 864256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular basis of activation of the alternative pathway of human complement.
    Austen KF; Fearon DT
    Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gangliosides on activation of the alternative pathway of human complement.
    Michalek MT; Bremer EG; Mold C
    J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A specific indicator for mouse lymphocyte C3b receptors.
    Linscott WD; Ranken R
    J Immunol; 1978 Jul; 121(1):221-4. PubMed ID: 670699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.